Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community PP405 timeframe ? Could it replace current treatments ?

      in Update  34 upvotes 11 months ago
      PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

      community cb-03-01 research chem (winlevi/clascoterone cream)

      in Technology  3 upvotes 2 years ago
      The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

      community Kintor’s GT20029 Phase 1 success

      in Update  74 upvotes 3 years ago
      Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

      community Breezula or kx-826 which one is better ?

      in Technology  3 upvotes 10 months ago
      Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

      community Why doesn't phase 3 of PP405 start straight away?

      in Chat  14 upvotes 6 months ago
      Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

      community PP405 Phase 2a press release with early results

      in Research/Science  700 upvotes 1 year ago
      PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.